Melphalan Tillomed (Melphalan)

Melphalan works by attaching alkyl groups to the N7 position of guanine bases in DNA, creating cross‑links that prevent DNA replication and transcription. This disruption triggers cell‑cycle arrest and apoptosis, particularly in rapidly dividing cancer cells, while also affecting normal proliferating tissues.

The specific dose of Melphalan Tillomed is determined by the treating physician based on the patient’s diagnosis, disease stage, body surface area, renal function and concurrent therapies. Dosing regimens are individualized and should follow the prescriber’s written order.

Safety data for melphalan in pregnancy and lactation are limited. Because the drug can cross the placenta and is excreted in breast milk, it is generally contraindicated in pregnant or nursing women unless the potential benefit justifies the risk. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Melphalan shares the DNA‑cross‑linking mechanism common to alkylating agents but differs in its pharmacokinetic profile and spectrum of activity. Compared with cyclophosphamide, melphalan is more lipophilic and often used in high‑dose conditioning regimens, while it may cause more pronounced myelosuppression and carries a higher risk of secondary leukaemia.

Melphalan Tillomed should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The vial must be kept in its original packaging until use, and any unused portion should be discarded according to local hazardous‑drug disposal regulations.

The product is supplied as a sterile injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a period of 30‑60 minutes, with appropriate pre‑hydration and anti‑emetic prophylaxis as per institutional protocols.

The most critical risks include severe myelosuppression leading to infection, anemia or bleeding; secondary malignancies such as acute leukaemia; organ toxicities like renal failure, pulmonary fibrosis and hemorrhagic cystitis; and rare but life‑threatening allergic reactions. Continuous monitoring is essential.

Melphalan is contraindicated in patients with known hypersensitivity to melphalan or other alkylating agents, in those with severe bone‑marrow failure, uncontrolled infections, or significant renal or hepatic impairment that cannot be corrected. It should also be avoided in pregnant women unless absolutely necessary.